Invex Therapeutics Ltd
ASX:IXC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shaanxi Sirui Advanced Materials Co Ltd
SSE:688102
|
CN |
Invex Therapeutics Ltd
Intangible Assets
Invex Therapeutics Ltd
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Invex Therapeutics Ltd
ASX:IXC
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Intangible Assets
AU$545.8m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Intangible Assets
AU$25.6k
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Invex Therapeutics Ltd
Glance View
Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2019-07-05. The firm is focused on the development and commercialisation of Presendin (Exenatide) for neurological conditions relating to raised intracranial pressure. The firm received written responses from the United States Food and Drug Administration (FDA) Division of Neurology relating to its proposed Phase III clinical trial design for Presendin in Idiopathic Intracranial Hypertension (IIH). Exenatide is a glucagon-like peptide-1 receptor agonist approved for the treatment of type II diabetes. The firm focuses on reformulating Exenatide to deliver it in a way that enables exploitation of its unknown ability to reduce cerebral spinal fluid secretion in the choroid plexus of the brain. The firm intends to progress expediently to clinical evaluation and undertake the registration of different formulations of Exenatide optimized to treat different neurological conditions.
